CDMOs need to be aware that unfavorable public markets put emerging bio/pharma R&D spending at risk in 2017.
Acquisition binges often lead to hangovers; here’s what to watch out for.
Demand is driving expansion and consolidation of formulation and clinical trial materials services.
Heightened global uncertainty could slow bio/pharma development activity.
CMO industry consolidation may be frustrated by a dearth of attractive assets.
Despite emergence of biologics, small-molecule APIs benefit from industry growth.
While all market signs are pointing up, memories of past setbacks may discourage CDMOs from expanding capacity.
Big service providers get bigger faster thanks to Big Pharma.
Market forces may limit the success of CMOs.
European CDMOs want into the US market, but entry options are limited.